Evidence map›Paper›PMID 38886308›Full record

ArticleMolecular biotechnology2025

Haplotype Inference Using Long-Read Nanopore Sequencing: Application to GSTA1 Promoter.

Vid Mlakar, Isabelle Dupanloup, Yvonne Gloor, Marc Ansari

Abstract read
In one paragraph

Article in Molecular biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Vid MlakarCANSEARCH Research Laboratory, Geneva University Medical School, Rue Michel Servet 1, 1211, Geneva, Switzerland. vid.mlakar@unige.ch.ORCID http://orcid.org/0000-0003-4968-5592
Isabelle DupanloupCANSEARCH Research Laboratory, Geneva University Medical School, Rue Michel Servet 1, 1211, Geneva, Switzerland.
Yvonne GloorCANSEARCH Research Laboratory, Geneva University Medical School, Rue Michel Servet 1, 1211, Geneva, Switzerland.
Marc AnsariCANSEARCH Research Laboratory, Geneva University Medical School, Rue Michel Servet 1, 1211, Geneva, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recovering true haplotypes can have important clinical consequences. The laboratory process is difficult and is, therefore, most often done through inference. In this paper, we show that when using the Oxford nanopore sequencing technology, we could recover the true haplotypes of the GSTA1 promoter region. Eight LCL cell lines with potentially ambiguous haplotypes were used to characterize the efficacy of Oxford nanopore sequencing to phase the correct GSTA1 promoter haplotypes. The results were compared to Sanger sequencing and inferred haplotypes in the 1000 genomes project. The average read length was 813 bp out of a total PCR length of 1336 bp. The best coverage of sequencing was in the middle of the PCR product and decreased to 50% at the PCR ends. SNPs separated by less than 200 bp showed > 90% of correct haplotypes, while at the distance of 1089 bp, this proportion still exceeded 58%. The number of cycles influences the generation of hybrid haplotypes but not extension or annealing time. The results demonstrate that this long sequencing reads methodology, can accurately determine the haplotypes without the need for inference. The technology proved to be robust but the success of phasing nonetheless depends on the distances and frequencies of SNPs.

Indexed as

HaplotypesNanopore SequencingPromoter Regions, GeneticCell LineHigh-Throughput Nucleotide SequencingHumansPolymorphism, Single NucleotideSequence Analysis, DNAGSTA1HaplotypesNanoporePhasingSequencing

Identifiers

PMID38886308
PMCPMC12055866

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.